39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs).
Saved in:
| Title: | 39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs). |
|---|---|
| Authors: | Raimondi, A.1 (AUTHOR), Tinè, G.2 (AUTHOR), De Stefano, A.3 (AUTHOR), Ballhausen, A.4 (AUTHOR), Bouche, O.5 (AUTHOR), Morano, F.1 (AUTHOR), Stahler, A.4 (AUTHOR), Romano, C.3 (AUTHOR), Prisciandaro, M.1 (AUTHOR), Randon, G.1 (AUTHOR), Gourgou, S.6 (AUTHOR), Alig, A.H.S.4 (AUTHOR), Cassata, A.3 (AUTHOR), Fazio, R.1 (AUTHOR), Brument, E.7 (AUTHOR), Miceli, R.2 (AUTHOR), Boige, V.8 (AUTHOR), Avallone, A.3 (AUTHOR), Modest, D.P.4 (AUTHOR), Pietrantonio, F.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 1, Vol. 36, pS24-S24. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
